ArticlePloS one2026
Hepatic transcriptomic responses in gravid and non-gravid rats exposed to HFPO-DA: Analyses to inform the role of maternal effects in neonatal toxicity.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integration of mechanistic and repeat dose toxicity data in the derivation of an oral reference dose for HFPO-DA.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Like many per- and polyfluoroalkyl substances (PFAS), toxicity studies for short-chain HFPO-DA (ammonium, 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate) indicate the liver is the primary target of toxicity in rodents. However, neonatal mortality and decreased birth weight have also been reported in rats following oral exposure to HFPO-DA in utero. Additional exposure-related effects in neonatal rats included hypoglycemia, decreased liver glycogen, and perturbed hepatic expression of genes related to glucose metabolism and peroxisome proliferator activated receptor (PPAR) signaling. A putative rodent-specific adverse outcome pathway (AOP) network was recently developed using these endpoints and assessed for its applicability to PFAS. AOP 1 in this putative AOP network consists of PPARα activation as one of multiple initiating events, with placental insufficiency, neonatal hepatic glycogen deficit, and hypoglycemia as key events leading to neonatal mortality and lower birth weight. To further inform AOP 1 and investigate whether this altered carbohydrate metabolism liver phenotype observed in rat neonates also occurs in HFPO-DA-exposed gravid and non-gravid adult rats, transcriptomic analysis and glycogen staining were performed on archived female rat liver samples from a 15-d developmental and 90-d subchronic toxicity study. HFPO-DA-mediated changes in hepatic gene expression in adult female rats were consistent with PPARa signaling. Changes in hepatic glycogen content and glucose metabolism-related gene expression did not appear to be dependent on HFPO-DA exposure, suggesting that the altered carbohydrate metabolism phenotype observed in neonatal rat livers is not likely to occur in adult female rats, regardless of pregnancy status. Therefore, key events in this AOP for neonatal mortality and lower birthweight are likely limited to the placenta and/or perinatal rat and are unlikely to be secondary to changes in carbohydrate metabolism in maternal liver. Additionally, findings from this study are consistent with previous mechanistic studies supporting the rodent-specific PPARα mode of action for HFPO-DA-mediated liver effects in rodents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.